Finch Therapeutics Group, Inc. (FNCH) · 10+ Years of Financial statements

Income Statement	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Sales/Revenue/Turnover	10	8	19	1	- -
+ Sales & Services Revenue	10	8	19	1	- -
- Cost of Revenue	- -	- -	- -	- -	- -
+ Cost of Goods & Services	- -	- -	- -	- -	- -
Gross Profit	10	8	19	1	- -
+ Other Operating Income	- -	- -	- -	- -	- -
- Operating Expenses	31	47	79	89	34
+ Selling, General & Admin	7	14	21	36	27
+ Research & Development	24	33	57	53	7
+ Other Operating Expense	- -	- -	- -	- -	- -
Operating Income (Loss)	-21	-39	-60	-88	-34
- Non-Operating (Income) Loss	- -	- -	-2	26	44
+ Interest Expense, Net	- -	- -	- -	- -	-2
+ Interest Expense	- -	- -	- -	- -	- -
- Interest Income	- -	- -	- -	- -	2
+ Other Non-Op (Income) Loss	- -	- -	-2	27	46
Pretax Income	-21	-39	-58	-115	-78
- Income Tax Expense (Benefit)	- -	- -	- -	- -	-3
- (Income) Loss from Affiliates	- -	- -	- -	- -	- -
Income (Loss) from Cont Ops	-21	-39	-58	-115	-75
- Net Extraordinary Losses (Gains)	- -	- -	- -	- -	- -
+ Discontinued Operations	- -	- -	- -	- -	- -
+ Extraord. & Accounting Changes	- -	- -	- -	- -	- -
Income (Loss) Incl. MI	-21	-39	-58	-115	-75
- Minority Interest	- -	- -	- -	- -	- -
Net Income, GAAP	-21	-39	-58	-115	-75
- Preferred Dividends	- -	- -	- -	- -	- -
- Other Adjustments	- -	- -	- -	- -	- -
Net Income Avail to Common, GAAP	-21	-39	-58	-115	-75
Basic Weighted Avg Shares	1	2	1	2	2
Basic EPS, GAAP	-17.95	-25.71	-44.5	-72.1	-46.58
Basic EPS from Cont Ops	-17.95	-25.71	-44.5	-72.1	-46.58
Diluted Weighted Avg Shares	1	2	1	2	2
Diluted EPS, GAAP	-17.95	-25.71	-44.5	-72.1	-46.58
Diluted EPS from Cont Ops	-17.95	-25.71	-44.5	-72.1	-46.58
EBITDA	-21	-39	-58	-83	-32
EBITDA Margin (%)	-203.47	-500.66	-311.27	-9,603.6	-30,357.01
EBITA	-21	-39	-60	-88	-34
EBIT	-21	-39	-60	-88	-34
Gross Margin (%)	96.91	100	100	100	100
Operating Margin (%)	-208.21	-510.9	-323.68	-10,243.21	-31,777.57
Profit Margin (%)	-204.39	-509.66	-313.84	-13,315.45	-69,863.55
Sales per Employee	- -	58,924	98,053	47,833	107,000
Dividend per Share	- -	- -	- -	- -	- -
Depreciation Expense	- -	1	2	6	2

Balance Sheet	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Total Current Assets	49	106	143	75	26
+ Cash, Cash Equivalents & STI	42	100	133	71	25
+ Cash & Cash Equivalents	42	100	133	71	25
+ ST Investments	- -	- -	- -	- -	- -
+ Accounts & Notes Receiv	5	1	- -	- -	- -
+ Accounts Receivable, Net	1	1	- -	- -	- -
+ Notes Receivable, Net	- -	- -	- -	- -	- -
+ Loans Receivable, Net	- -	- -	- -	- -	- -
+ Other Receivable, Net	4	- -	- -	- -	- -
+ Inventories	- -	- -	- -	- -	- -
+ Raw Materials	- -	- -	- -	- -	- -
+ Work In Process	- -	- -	- -	- -	- -
+ Finished Goods	- -	- -	- -	- -	- -
+ Inventory Adjustments	- -	- -	- -	- -	- -
+ Other Inventory	- -	- -	- -	- -	- -
+ Other ST Assets	2	5	9	3	1
+ Prepaid Expenses	- -	- -	- -	- -	- -
+ ST Derivative & Hedging Assets	- -	- -	- -	- -	- -
+ ST Assets Held-for-Sale	- -	- -	- -	- -	- -
+ ST Deferred Tax Assets	- -	- -	- -	- -	- -
+ Misc ST Assets	- -	- -	- -	- -	- -
Total Noncurrent Assets	55	59	83	88	30
+ Property, Plant & Equip, Net	4	7	25	49	27
+ Property, Plant & Equip	5	9	29	58	27
- Accumulated Depreciation	1	2	4	9	- -
+ LT Investments & Receivables	- -	- -	- -	- -	- -
+ LT Investments	- -	- -	- -	- -	- -
+ LT Receivables	- -	- -	- -	- -	- -
+ Other LT Assets	51	52	58	40	2
+ Total Intangible Assets	51	51	51	33	- -
+ Goodwill	18	18	18	- -	- -
+ Other Intangible Assets	33	33	33	33	- -
+ LT Deferred Tax Assets	- -	- -	- -	- -	- -
+ LT Derivative & Hedging Assets	- -	- -	- -	- -	- -
+ Misc LT Assets	- -	1	7	7	2
Total Assets	104	165	225	163	55
+ Payables & Accruals	3	5	9	11	2
+ Accounts Payable	1	3	4	1	- -
+ Accrued Taxes	- -	- -	- -	1	- -
+ Interest & Dividends Payable	- -	- -	- -	- -	- -
+ Other Payables & Accruals	2	2	6	9	2
+ ST Debt	- -	- -	1	3	2
+ ST Borrowings	- -	- -	- -	- -	- -
+ ST Finance Leases	- -	- -	1	3	2
+ Other ST Liabilities	5	7	4	1	- -
+ Deferred Revenue	2	3	- -	- -	- -
+ Derivatives & Hedging	- -	- -	- -	- -	- -
+ Deferred Tax Liabilities	- -	- -	- -	- -	- -
+ Misc ST Liabilities	2	4	4	1	- -
Total Current Liabilities	7	11	15	15	4
+ LT Debt	- -	2	5	49	28
+ LT Borrowings	- -	2	- -	15	- -
+ LT Finance Leases	- -	- -	5	34	28
+ Other LT Liabilities	156	248	3	4	- -
+ Accrued Liabilities	12	14	3	3	- -
+ Pension Liabilities	- -	- -	- -	- -	- -
+ Deferred Revenue	- -	- -	- -	- -	- -
+ Deferred Tax Liabilities	- -	- -	- -	- -	- -
+ Derivatives & Hedging	- -	- -	- -	- -	- -
+ Misc LT Liabilities	144	233	- -	- -	- -
Total Noncurrent Liabilities	156	250	8	53	28
Total Liabilities	163	261	23	67	32
+ Preferred Equity and Hybrid Capital	- -	- -	- -	- -	- -
+ Share Capital & APIC	4	7	363	371	373
+ Common Stock	- -	- -	- -	- -	- -
+ Additional Paid in Capital	4	7	363	371	373
- Treasury Stock	- -	- -	- -	- -	- -
+ Retained Earnings	-63	-103	-161	-276	-350
+ Other Equity	- -	- -	- -	- -	- -
Equity Before Minority Interest	-60	-96	202	96	23
+ Minority/Non Controlling Interest	- -	- -	- -	- -	- -
Total Equity	-60	-96	202	96	23
Total Liabilities & Equity	104	165	225	163	55
Shares Outstanding	1	2	2	2	2
Capital Leases - Total	- -	- -	6	38	30
Net Debt	-42	-98	-133	-56	-25
Net Debt to Equity	70.86	102.28	-66.01	-58.91	-109.78
Tangible Common Equity Ratio	-210.01	-128.23	86.73	48.3	41.33
Current Ratio	6.64	9.24	9.64	5.08	6.33
Cash Conversion Cycle	- -	- -	- -	- -	- -
Number of Employees	- -	131	189	18	1

Cash Flow Statement	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
+ Net Income	-21	-39	-58	-115	-75
+ Depreciation & Amortization	- -	1	2	6	2
+ Non-Cash Items	1	3	3	36	47
+ Stock-Based Compensation	1	3	4	8	2
+ Deferred Income Taxes	- -	- -	- -	- -	-3
+ Asset Impairment Charge	- -	- -	- -	25	46
+ Other Non-Cash Adj	- -	- -	-1	3	3
+ Chg in Non-Cash Work Cap	2	4	-15	-2	-5
+ (Inc) Dec in Accts Receiv	- -	4	1	- -	- -
+ (Inc) Dec in Inventories	- -	- -	- -	- -	- -
+ (Inc) Dec in Prepaid Assets	- -	-4	-3	-3	2
+ Inc (Dec) in Accts Payable	1	1	7	-2	-9
+ Inc (Dec) in Other	1	3	-19	3	1
+ Net Cash From Disc Ops	- -	- -	- -	- -	- -
Cash from Operating Activities	-17	-31	-67	-75	-32
+ Change in Fixed & Intang	- -	- -	- -	- -	- -
+ Disp in Fixed & Intang	- -	- -	- -	- -	1
+ Disp of Fixed Prod Assets	- -	- -	- -	- -	1
+ Disp of Intangible Assets	- -	- -	- -	- -	- -
+ Acq of Fixed & Intang	-1	-3	-16	-2	- -
+ Acq of Fixed Prod Assets	-1	-3	-16	-2	- -
+ Acq of Intangible Assets	- -	- -	- -	- -	- -
+ Net Change in LT Investment	- -	- -	- -	- -	- -
+ Dec in LT Investment	- -	- -	- -	- -	- -
+ Inc in LT Investment	- -	- -	- -	- -	- -
+ Net Cash From Acq & Div	- -	- -	- -	- -	- -
+ Cash from Divestitures	- -	- -	- -	- -	- -
+ Cash for Acq of Subs	- -	- -	- -	- -	- -
+ Cash for JVs	- -	- -	- -	- -	- -
+ Other Investing Activities	- -	- -	- -	- -	- -
+ Net Cash From Disc Ops	- -	- -	- -	- -	- -
Cash from Investing Activities	-1	-3	-16	-2	1
+ Dividends Paid	- -	- -	- -	- -	- -
+ Net Cash From Debt	5	2	- -	15	-16
+ Cash From Debt	5	2	- -	15	- -
+ Repayments of Debt	- -	- -	- -	- -	-16
+ Cash (Repurchase) of Equity	- -	- -	119	- -	- -
+ Increase in Capital Stock	- -	- -	119	- -	- -
+ Decrease in Capital Stock	- -	- -	- -	- -	- -
+ Other Financing Activities	49	90	1	- -	- -
+ Net Cash From Disc Ops	- -	- -	- -	- -	- -
Cash from Financing Activities	53	91	119	15	-16
Effect of Foreign Exchange Rates	- -	- -	- -	- -	- -
Net Changes in Cash	35	58	36	-62	-46
Capital Expenditures	-1	-3	-16	-2	- -
EBITDA	-21	-39	-58	-83	-32
EBITDA Margin (%)	-203.47	-500.66	-311.27	-9,603.6	-30,357.01
Net Cash Paid for Acquisitions	- -	- -	- -	- -	- -
Free Cash Flow	-18	-34	-83	-77	-32
Free Cash Flow to Firm	- -	- -	- -	- -	- -
Free Cash Flow to Equity	- -	-32	-83	-62	-46
Free Cash Flow per Basic Share	-15.85	-22.2	-63.59	-48.45	-19.63
Price/Free Cash Flow	- -	- -	-7.7	-0.3	-0.2
Cash Flow to Net Income	0.83	0.8	1.15	0.65	0.42

Finch Therapeutics Group, Inc.

FNCH US

1.48